Glyxambi is a prescription tablet for adults with type 2 diabetes that combines empagliflozin and linagliptin. It is used with diet and exercise to help improve blood glucose control when both drug actions are appropriate. The main issues to understand are how the two ingredients work, who may be a suitable candidate, what side effects can occur, and how dosing is usually approached.
This article explains the clinical basics in plain language. It does not replace your prescriber’s advice, especially if you have kidney disease, recurrent urinary infections, low blood pressure, or take insulin or sulfonylureas.
Key Takeaways
- Two mechanisms: It combines an SGLT2 inhibitor and a DPP-4 inhibitor.
- Type 2 use: It is intended for adults with type 2 diabetes.
- Daily routine: It is usually taken once daily, often in the morning.
- Safety focus: Genital infections, urinary issues, dehydration, and ketoacidosis need attention.
- Not interchangeable: It is not the same as empagliflozin alone or metformin.
What Glyxambi Is and Why It Is Used
Glyxambi contains empagliflozin and linagliptin in one fixed-dose tablet. Empagliflozin is a sodium-glucose cotransporter 2 inhibitor, often shortened to SGLT2 inhibitor. It helps the kidneys remove extra glucose through urine. Linagliptin is a dipeptidyl peptidase-4 inhibitor, or DPP-4 inhibitor. It helps incretin hormones support meal-related insulin release and reduce excess glucagon.
The labeled Glyxambi uses center on improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is not used for type 1 diabetes. It is also not a treatment for diabetic ketoacidosis, a dangerous buildup of acids called ketones in the blood.
Why this matters: a fixed-dose combination can reduce pill burden, but it also means both active ingredients must fit your medical situation. Your clinician considers A1C trends, kidney function, infection history, other diabetes medicines, and cardiovascular or kidney risk factors before choosing a regimen.
For broader condition context, the Type 2 Diabetes collection includes related educational reading. For class-level context on DPP-4 medicines, see Taking DPP-4 Inhibitors.
How the Two Ingredients Work Together
The two ingredients lower glucose through different pathways, which is the main reason this combination exists. Empagliflozin acts in the kidneys, while linagliptin acts through incretin hormone signaling. Together, they may help address fasting and post-meal glucose patterns without using the same biological route twice.
Empagliflozin: the SGLT2 component
Empagliflozin lowers the amount of glucose reabsorbed by the kidneys. More glucose leaves the body in urine. This action can also cause more urination and mild fluid loss. Some people may notice modest weight change because glucose calories are lost in urine, but Glyxambi weight loss is not the primary purpose of treatment.
SGLT2 medicines require attention to hydration, kidney function, and infection symptoms. People who are older, take diuretics, have low blood pressure, or become ill with vomiting or diarrhea may be more vulnerable to dehydration.
Linagliptin: the DPP-4 component
Linagliptin blocks the DPP-4 enzyme, which helps incretin hormones last longer. These hormones help the pancreas release insulin after meals and reduce glucagon when glucose is elevated. This effect is generally glucose-dependent, so DPP-4 inhibitors have a lower risk of hypoglycemia when used without insulin or sulfonylureas.
Linagliptin is also available as a separate medicine. For readers comparing DPP-4 options, Linagliptin vs Januvia explains how two drugs in this class differ.
Dosing Basics, Strengths, and Daily Timing
Glyxambi dosage is individualized, but the medicine is generally taken once daily. Product labeling describes morning administration, with or without food. Taking it at the same time each day can make missed doses less likely and helps your care team interpret glucose patterns more clearly.
The fixed-dose strengths include Glyxambi 10/5 and Glyxambi 25/5. These shorthand names refer to empagliflozin 10 mg or 25 mg combined with linagliptin 5 mg. Some people also write the higher strength as Glyxambi 25mg/5mg. Your prescriber decides whether a starting strength or higher strength is appropriate based on response, kidney function, tolerability, and other medicines.
Do not change between strengths without medical guidance. A higher tablet strength is not simply a stronger version for everyone. It increases the empagliflozin component while the linagliptin amount remains the same, so the risk-benefit discussion mainly changes around the SGLT2 portion.
Quick tip: Keep a current medication list that includes tablet strength and timing.
Side Effects and Safety Signals to Watch
Glyxambi side effects can reflect either component, but many common issues come from the SGLT2 ingredient. Commonly reported effects include genital yeast infections, urinary tract infections, increased urination, stuffy or runny nose, and symptoms related to fluid loss. Dizziness may occur if blood pressure drops or dehydration develops.
Genital yeast infections can cause itching, redness, soreness, discharge, or irritation. Urinary tract infections may cause burning, urgency, pelvic discomfort, cloudy urine, or fever. Contact a clinician if symptoms are persistent, severe, or recurrent.
Serious but less common risks include diabetic ketoacidosis, severe urinary tract infection, acute kidney injury, severe allergic reactions, and a rare but dangerous genital-area infection called necrotizing fasciitis of the perineum. Seek urgent care for symptoms such as nausea, vomiting, abdominal pain, unusual tiredness, trouble breathing, confusion, fever with genital pain or swelling, or signs of severe dehydration.
Low blood sugar is not usually expected from this combination alone. The risk can rise when it is used with insulin or medicines that increase insulin release, such as sulfonylureas. Your prescriber may review your broader regimen if repeated lows occur.
For a wider safety comparison across diabetes therapies, see Type 2 Diabetes Medication Side Effects.
Kidney, Heart, and Eligibility Considerations
Kidney function matters because empagliflozin works through the kidneys. Clinicians often check estimated glomerular filtration rate, or eGFR, before and during SGLT2 therapy. The question “is Glyxambi safe for kidneys” depends on your kidney function, hydration status, other medications, and reason for treatment.
Some SGLT2 medicines have evidence for cardiovascular and kidney-related benefits in certain populations, but that does not make every product or combination appropriate for every person. The official label and current clinical guidance should shape decisions. People with severe kidney impairment, dialysis, frequent dehydration, or recurrent genital or urinary infections may need a different plan.
Tell your clinician about pregnancy, plans for pregnancy, breastfeeding, pancreatitis history, gallbladder disease, heavy alcohol use, very low-carbohydrate dieting, upcoming surgery, or acute illness. These factors can affect SGLT2 or DPP-4 safety. During illness, reduced food intake and fluid loss can change diabetes medication risk, so ask your care team about sick-day instructions in advance.
Why it matters: Safety depends on the whole regimen, not one tablet alone.
How It Compares With Common Alternatives
Glyxambi is not the same as Jardiance. Jardiance contains empagliflozin only, while Glyxambi combines empagliflozin with linagliptin. That means the combination adds DPP-4 activity but also adds another ingredient to consider for side effects, interactions, and suitability. For product-level navigation, see Jardiance 10 and 25 mg.
Glyxambi vs metformin is a different comparison. Metformin is often used as a foundational type 2 diabetes medicine when tolerated and appropriate. It works mainly by reducing liver glucose production and improving insulin sensitivity. Glyxambi works through kidney glucose excretion and incretin signaling. One is not automatically “better” than the other; the right choice depends on glucose goals, kidney function, side effect history, cardiovascular considerations, and medication access.
A Glyxambi 25/5 substitute may involve separate components, an SGLT2-only medicine, a DPP-4-only medicine, metformin-based combinations, or another diabetes class. Substitution should be clinician-led because each option changes dosing, monitoring, and cautions. For an example of an SGLT2 and metformin combination, see Synjardy Uses and Side Effects. For a comparison involving an SGLT2 medicine and a DPP-4/metformin option, see Jardiance vs Janumet.
Generic Status, Manufacturer, and Access Context
Many readers ask about a Glyxambi generic because branded combination tablets can be costly. Availability of generic equivalents can vary by country, patent status, pharmacy sourcing, and regulatory approval. If generic substitution is important, ask a pharmacist whether an approved equivalent is available in your jurisdiction and whether separate ingredients are an option.
The Glyxambi manufacturer is Boehringer Ingelheim, with Eli Lilly involved in the diabetes alliance behind several related products. Manufacturer information can help identify official patient materials, but treatment decisions should still rely on labeling, clinician guidance, and your medical history.
People also ask why Glyxambi is so expensive. Branded fixed-dose medicines can cost more because of patent protection, product development, formulary placement, and supply-chain factors. Out-of-pocket cost may differ depending on insurance coverage, pharmacy channel, and whether a separate-component regimen is allowed.
CanadianInsulin.com is a prescription referral platform, and prescription details may be confirmed with the prescriber when required. Dispensing and fulfillment are handled by licensed third-party pharmacies where permitted. Some patients compare cash-pay options or cross-border fulfillment depending on eligibility and local rules.
To browse related medication categories without treating them as direct substitutes, use the Diabetes Products section or the Type 2 Diabetes Products listing.
Practical Questions to Bring to Your Clinician
A short question list can make medication reviews more useful. Bring recent A1C results, home glucose trends, kidney labs if available, and a full list of prescription and nonprescription medicines. Include supplements and diuretics, because they can affect hydration or blood pressure.
- Fit: Why are both ingredients appropriate for me?
- Kidneys: What kidney tests should be monitored?
- Infections: What symptoms should I report quickly?
- Low sugars: Do my other medicines raise hypoglycemia risk?
- Illness plan: What should I do during vomiting or poor intake?
- Alternatives: What options exist if cost or side effects become limiting?
If you use continuous glucose monitoring or frequent finger-stick readings, ask how your team wants patterns reported. Do not stop or restart diabetes medicines on your own unless a clinician has given specific instructions for that situation.
Authoritative Sources
For label-backed details on indications, dosing, warnings, and contraindications, review the FDA-approved prescribing information for Glyxambi.
For patient-friendly information on the SGLT2 ingredient, see MedlinePlus information on empagliflozin.
For patient-friendly information on the DPP-4 ingredient, see MedlinePlus information on linagliptin.
Bottom Line
Glyxambi may be useful when an adult with type 2 diabetes needs the combined actions of empagliflozin and linagliptin in one tablet. The same combination also requires careful attention to hydration, kidney function, infection symptoms, and other glucose-lowering medicines. If side effects, cost, or monitoring concerns arise, discuss alternatives rather than changing treatment alone.
This content is for informational purposes only and is not a substitute for professional medical advice.
